Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Losartan Potassium NDC 70518-3282 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Losartan Potassium 50mg 70518 3282 01
Losartan Potassium is a tablet of 50 mg quantity made by Lupin Pharma located in Baltimore, MD with an NDC number of 70518-3282-01 and source NDC of 68180-0377-03. It is packed by RemedyRepack Inc., Indiana, PA 15701. The expiration date and lot number are not available. Keep this medication away from the reach of children. See package insert for directions on usage. It should be stored at a temperature of 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP].*
Remedy_Label - Remedy Label
Losartan Potassium is a medication that comes in the form of 50mg tablets packed in a quantity of 60. The NDC number is 70518-3282-00 and the medication is manufactured by Lupin Pharma based in Baltimore, MD 21202. The label warns to keep the medication out of the reach of children and provides directions to use through the package insert. The medication should be stored at 20-26°C (63-77°F), with excursions permitted up to 15-30°C (59-86°F) [See USP]. The medication was repackaged by RemedyRepack Inc. located in Indiana, PA 15701, 724.466.8762.*
image - a27c3ddf 3129 4f3e bc0e 37381cc1a167 01
image - a27c3ddf 3129 4f3e bc0e 37381cc1a167 02
The text is a comparative analysis of two medicines, Atenolol and Losartan, on a certain primary endpoint, presented in the form of percentage. It also includes information on the adjusted risk reduction and p-value. Additionally, there is a graph showing the study month timeline.*
image - a27c3ddf 3129 4f3e bc0e 37381cc1a167 03
This text provides data on the percentage of patients who experienced fatal or non-fatal stroke when treated with Atenolol or Losartan. The adjusted risk reduction for this outcome was 25%, and the statistical significance of this result was p=0.001. The data is presented over a period of 66 months, with stroke incidence measured at different intervals.*
image - a27c3ddf 3129 4f3e bc0e 37381cc1a167 04
This appears to be a medical report showing the results of a study comparing the efficacy of two drugs, Losartan and Atenolol, in reducing the incidence of stroke and cardiovascular disease in diabetic and non-diabetic patients of different ages and genders. The report shows the number of patients, event rates, hazard ratios, and confidence intervals for different subgroups. Overall, it seems that Losartan is slightly more effective than Atenolol in reducing cardiovascular events.*
image - a27c3ddf 3129 4f3e bc0e 37381cc1a167 05
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.